On this page
Biostimulators / Liquid Facelift
Biostimulator is a general term for injectable products intended to encourage collagen production and connective-tissue support through a controlled biological response. Many treatments described as a “liquid facelift” use these products.
The term refers to injectable support and a firmer-looking appearance. It is not a surgical facelift: tissues are not cut and repositioned. Outcomes depend on the product, the starting tissue characteristics and individual response.
Are they the same as fillers?
Not exactly, although the distinction varies between products. CaHA can provide some early support through its carrier gel, whereas changes with PLLA and PDLLA depend mainly on the tissue response over time.
A biostimulator is not inherently a “more natural” or superior filler. Localised volume loss may favour filler treatment; broader support or skin-quality concerns may lead to consideration of a biostimulator. A measured combination may sometimes be appropriate.
CaHA, PLLA, PDLLA and PCL are different
- CaHA contains calcium hydroxylapatite microspheres in a carrier gel. Concentration and dilution influence whether it is used for structural support or more diffuse tissue-quality goals.
- PLLA, poly-L-lactic acid, is assessed through the collagen response developing over weeks and months rather than the immediate appearance. The number of sessions varies.
- PDLLA, poly-D,L-lactic acid, belongs to the same polymer family but differs from PLLA in particle structure and formulation. Similar names do not make products interchangeable.
- PCL contains polycaprolactone microspheres in a carboxymethylcellulose carrier gel. The gel provides early support while collagen response develops. The persistence of the product matters when choosing it and planning follow-up.
What changes may be possible?
Suitable patients may see changes in tissue support, skin quality and facial contours. Biostimulators cannot independently remove substantial excess skin or advanced sagging. A “liquid facelift” should not be understood as promising the result of surgery.
My priority is to identify where support has changed and whether treatment can meet that need, rather than enlarging the face or changing its expression.
Which areas may be considered?
The midface, lateral cheek region and jawline are areas I commonly assess. Product selection and tissue plane vary by area. Thin or highly mobile areas such as the lips and under-eyes are not suitable for every biostimulator.
What I assess at the first consultation
- Tissue needs: skin thickness, laxity, fat and bone support. Not every visible change is simply collagen loss.
- Previous treatment: filler and biostimulator types, timing, areas treated and any reactions.
- Expectations and timing: gradual changes, possible session plans and follow-up.
Treatment and development of results
A needle or cannula may be used depending on the product and area. Some plans involve one session; others require spaced sessions. Carrier fluid and swelling contribute to the immediate appearance, so it is not judged as the final result.
Collagen response develops gradually. Follow-up includes appearance and examination of the tissue, with further sessions planned after observing the initial response when appropriate.
When extra care is needed
Discuss pregnancy or breastfeeding, active infection or inflammation, immune-related illness, bleeding tendency, medication and unexpected reactions to earlier injections. Permanent or unidentified filler in the same area may change the plan.
Important safety information
CaHA, PLLA, PDLLA and PCL are not hyaluronic acid and cannot be dissolved with hyaluronidase. Superficial or uneven placement, product accumulation or delayed inflammation can cause palpable nodules. A granuloma is a less common delayed foreign-body reaction. Not every lump has the same cause, so diagnosis comes first.
As with other injections, vascular occlusion is an uncommon but serious risk. Unusually severe pain, whitening, grey-blue discolouration or visual changes require immediate contact with the treating doctor and emergency medical services when needed.
Frequently asked questions
Is a liquid facelift an alternative to surgery?
It describes injectable support, not surgical repositioning. It does not remove substantial excess skin or advanced sagging, so the two approaches do not promise equivalent results.
When might changes become noticeable?
CaHA and PCL can provide some early support through their gels, but early swelling is not the final result. Collagen-related change may become noticeable at around 4–8 weeks and more evident at two to three months. With PLLA and PDLLA, visible change often begins at 6–12 weeks and may develop over three to six months with a treatment series.
How many sessions are needed?
There is no standard number for everyone. The product, support loss, area and response guide the plan. Some people have one treatment; others need spaced sessions and review.
Can biostimulators make the face look swollen?
Enlargement is not the aim. Product properties, amount, tissue plane and early swelling affect appearance. Excessive or inappropriate treatment can disturb facial proportions.
Can they be dissolved?
These four materials cannot be dissolved with hyaluronidase. Managing a problem depends on the product and the specific finding, which makes selection and technique particularly important.
Can they be combined with fillers or botulinum toxin?
Sometimes these address different parts of the same plan, but they do not all have to be performed on the same day. Sequence and spacing depend on whether the concern arises from muscle movement, volume or tissue support.
Can nodules or granulomas occur?
Yes. Alongside temporary swelling and bruising, nodules and, less commonly, delayed inflammation or granulomas can occur. Consistent preparation, suitable placement and amount, and follow-up help reduce risk.
